within Pharmacolibrary.Drugs.S_SensoryOrgans.S01E_AntiglaucomaPreparationsAndMiotics.S01EX05_Netarsudil;

model Netarsudil
  extends Pharmacolibrary.Drugs.ATC.S.S01EX05;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>S01EX05</td></tr><td>route:</td><td>ophthalmic</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Netarsudil is a Rho kinase inhibitor used for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. It is approved for topical ophthalmic use.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters estimated for human subjects based on available product labeling and pharmacology reviews, as direct peer-reviewed pharmacokinetic profile studies are not published.</p><h4>References</h4><ol><li><p>Kopczynski, CC, &amp; Heah, T (2018). Netarsudil ophthalmic solution 0.02% for the treatment of patients with open-angle glaucoma or ocular hypertension. <i>Drugs of today (Barcelona, Spain : 1998)</i> 54(8) 467–478. DOI:<a href=\"https://doi.org/10.1358/dot.2018.54.8.2849627\">10.1358/dot.2018.54.8.2849627</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/30209441/\">https://pubmed.ncbi.nlm.nih.gov/30209441</a></p></li><li><p>Batra, M, et al., &amp; Morsy, MA (2021). Netarsudil: A new ophthalmic drug in the treatment of chronic primary open angle glaucoma and ocular hypertension. <i>European journal of ophthalmology</i> 31(5) 2237–2244. DOI:<a href=\"https://doi.org/10.1177/11206721211008783\">10.1177/11206721211008783</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/33843288/\">https://pubmed.ncbi.nlm.nih.gov/33843288</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end Netarsudil;
